B. Riley Research Analysts Boost Earnings Estimates for KYMR

Key Points

• Investment analysts at B. Riley have raised their Q3 2025 earnings estimates for Kymera Therapeutics, now forecasting earnings per share of ($0.98) compared to a previous estimate of ($1.04).
• B. Riley maintains a "Strong-Buy" rating and a target price of $60 for the stock, while the consensus rating across analysts is currently a "Buy."
• Kymera Therapeutics reported a Q2 earnings miss, posting ($0.95) EPS against a consensus estimate of ($0.83), reflecting a 55.1% year-over-year revenue decline.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Research analysts at B. Riley upped their Q3 2025 earnings per share (EPS) estimates for Kymera Therapeutics in a research report issued on Tuesday, August 12th. B. Riley analyst M. Mamtani now forecasts that the company will post earnings per share of ($0.98) for the quarter, up from their previous forecast of ($1.04). B. Riley currently has a "Strong-Buy" rating and a $60.00 price target on the stock. The consensus estimate for Kymera Therapeutics' current full-year earnings is ($2.79) per share. B. Riley also issued estimates for Kymera Therapeutics' Q4 2025 earnings at ($1.09) EPS, FY2025 earnings at ($3.82) EPS, FY2026 earnings at ($5.16) EPS, FY2027 earnings at ($5.81) EPS and FY2028 earnings at ($5.29) EPS.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its earnings results on Monday, August 11th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.12). The business had revenue of $11.48 million during the quarter, compared to the consensus estimate of $17.37 million. Kymera Therapeutics had a negative return on equity of 31.60% and a negative net margin of 616.03%.The firm's revenue for the quarter was down 55.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.58) earnings per share.

Several other research firms have also recently issued reports on KYMR. Stifel Nicolaus assumed coverage on Kymera Therapeutics in a research note on Tuesday, May 20th. They issued a "buy" rating and a $55.00 target price on the stock. HC Wainwright reissued a "buy" rating and issued a $60.00 target price (up from $54.00) on shares of Kymera Therapeutics in a research note on Thursday, June 26th. BTIG Research reissued a "buy" rating and issued a $59.00 target price on shares of Kymera Therapeutics in a research note on Thursday, June 26th. JPMorgan Chase & Co. upped their target price on Kymera Therapeutics from $57.00 to $64.00 and gave the stock an "overweight" rating in a report on Tuesday, June 3rd. Finally, Jefferies Financial Group set a $64.00 target price on Kymera Therapeutics and gave the stock a "buy" rating in a research report on Wednesday, June 25th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $59.11.

Kymera Therapeutics Stock Performance

Shares of NASDAQ KYMR traded down $0.6150 during trading hours on Thursday, hitting $43.0050. The company's stock had a trading volume of 213,965 shares, compared to its average volume of 746,282. The stock has a market cap of $3.07 billion, a price-to-earnings ratio of -12.39 and a beta of 2.18. Kymera Therapeutics has a 12 month low of $19.44 and a 12 month high of $53.27. The business has a 50-day simple moving average of $44.57 and a 200-day simple moving average of $36.47.

Insider Buying and Selling

In other news, Director Jeffrey W. Albers sold 6,349 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $49.00, for a total value of $311,101.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Bvf Partners L. P/Il purchased 317,167 shares of the company's stock in a transaction dated Monday, June 30th. The stock was bought at an average cost of $44.00 per share, for a total transaction of $13,955,348.00. Following the completion of the transaction, the director owned 2,798,795 shares in the company, valued at approximately $123,146,980. This represents a 12.78% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 48,349 shares of company stock worth $2,334,301 over the last quarter. Company insiders own 16.01% of the company's stock.

Institutional Trading of Kymera Therapeutics

Hedge funds have recently made changes to their positions in the stock. Farther Finance Advisors LLC boosted its position in shares of Kymera Therapeutics by 642.9% in the 2nd quarter. Farther Finance Advisors LLC now owns 624 shares of the company's stock worth $27,000 after purchasing an additional 540 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Kymera Therapeutics by 506.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company's stock worth $40,000 after purchasing an additional 770 shares in the last quarter. State of Wyoming bought a new stake in shares of Kymera Therapeutics in the 4th quarter worth approximately $45,000. GF Fund Management CO. LTD. bought a new stake in shares of Kymera Therapeutics in the 4th quarter worth approximately $55,000. Finally, KBC Group NV boosted its position in shares of Kymera Therapeutics by 15.2% in the 1st quarter. KBC Group NV now owns 2,479 shares of the company's stock worth $68,000 after purchasing an additional 328 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.